Semax is a synthetic ACTH-derived peptide registered as a medicine in Russia. Cognitive and attention claims rely mainly on Russian-language clinical and preclinical publications, with limited independent replication and no FDA approval in the United States.
Research peptide
Semax
Semax is a synthetic ACTH-derived peptide registered as a medicine in Russia. Cognitive and attention claims rely mainly on Russian-language clinical and preclinical publications, with limited independent replication and no FDA approval in the United States.
Regulatory watch
Last reviewed Jul 12, 2026
Next review Jul 24, 2026
Evidence snapshot
Regulatory status: Semax is registered as a medicine in Russia but is not FDA-approved in the United States.
Clinical evidence: the reviewed publications are primarily Russian-language studies from Russian institutions.
Replication gap: independent Western clinical confirmation remains limited.
U.S. policy: Semax was scheduled for FDA advisory committee discussion in July 2026.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- Semax regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for Semax is pending editorial assessment. Current summary reflects available public records.
Records: FDA compounding advisory committee July 2026: peptides, FDA BPC-157 compounding safety risk: immunogenicity, Semax: cognitive and attention effects in clinical and preclinical studies
Evidence timeline
What changed, and when
Peptide Report last reviewed Semax on 2026-07-12.
Records: FDA compounding advisory committee July 2026: peptides
Direct answers
Frequently asked questions
What is Semax?
Semax is a research peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for Semax?
- What are the long-term safety considerations for Semax?
Tracked claims
Semax is part of the FDA advisory committee peptide discussion set.
Evidence level: Primary regulatory
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: The advisory proceeding concerns U.S. compounding policy and does not establish clinical efficacy.
Russian-language clinical publications describe cognitive and attention-enhancing effects of Semax, but these studies lack independent Western replication.
Evidence level: Peer reviewed
Sources: Semax: cognitive and attention effects in clinical and preclinical studies
How to read this: Semax is a heptapeptide ACTH analog registered as a medicine in Russia. Studies are primarily from Russian institutions and have not been replicated in Western clinical trials.
Semax is discussed in biohacking communities as a cognitive enhancer despite its lack of FDA approval or regulatory recognition outside Russia.
Evidence level: Community discussion
Sources: Semax: cognitive and attention effects in clinical and preclinical studies, FDA BPC-157 compounding safety risk: immunogenicity
How to read this: Track community cognitive-enhancement claims as source-discovery signals. The FDA bulk risk list applies to compounded peptide products marketed in the United States.
Linked public records
Regulatory actions involving Semax
FDA advisory committee to review seven peptide-related bulk drug substances
Scheduled · Scheduled public meeting
FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.
Compounds: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Semax claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA Pharmacy Compounding Advisory Committee meeting notice for July 23 to 24, 2026, scheduling peptide bulk substances for discussion.
23 linked pagesOpen original ·
fda-pcac-july-2026Certain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-listSemax: cognitive and attention effects in clinical and preclinical studies
Russian-language clinical and preclinical publications on Semax (a heptapeptide ACTH analog) describing cognitive and attention-enhancing effects. Studies are primarily from Russian institutions and lack independent Western replication.
5 linked pagesOpen original ·
pubmed-semax-cognitive-2006Related compounds
BPC-157
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry re...
Regulatory watchDSIP
Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results ...
Regulatory watchEpitalon
Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests la...
Regulatory watchKPV
KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come fr...
Regulatory watchStay informed